Nonalcoholic fatty liver disease is a chronic liver disease estimated to affect more than 20 percent of all American adults. It has strong links to diabetes, obesity and insulin resistance and can lead to cirrhosis and liver failure or cancer. Gastroenterologist Sanjay Ramrakhiani, M.D., discusses nonalcoholic fatty liver disease, its symptoms, complications and preventive measures.
Featured Services in Palo Alto
Expertise in Fatty Liver Disease
Nonalcoholic fatty liver disease presents in a variety of forms and can be diagnosed through diagnostic services, such as through a livery biopsy. Simple steatosis—signs of this often are discovered during routine blood tests—is the most common. Steatosis refers to the presence of fat deposits within liver cells, which damage the liver. Nonalcoholic steatohepatitis (NASH) causes inflammation and liver scar tissue or fibrosis. NASH-related cirrhosis, the most serious form, can lead to liver failure and require a liver transplant.
The Sutter Health network of care includes liver specialists with extensive expertise in caring for nonalcoholic fatty liver disease. The Fatty Liver Clinic at the California Pacific Medical Center in San Francisco is one of eight centers in the U.S. focusing on innovative research in this disease.
We offer comprehensive disease evaluation and management services, as well as access to clinical trials. We also participate in leading-edge research studies. Current research focuses on treatment with new medications, advanced liver imaging techniques, dietary interventions and genetic and metabolic studies.
In Your Corner
Defending the Liver from Cirrhosis
Many liver diseases, hepatitis B included, can cause cirrhosis, which hinders your liver's ability to perform its many functions. With early diagnosis and management, liver specialists in the Sutter Health network can help you stop and sometimes reverse the damage.
Liver Diseases and Transplant Research
Hepatology researchers are investigating the cellular and molecular mechanisms underlying hepatitis B, C and other liver diseases. Identifying early molecular or genetic changes - which may be detected before the disease manifests any clinical symptoms - could lead to interventions that reduce the severity of liver disease, or even prevent it from developing. Clinical researchers in the Liver Disease Management and Transplant Program are leading new investigations into hepatitis B and C disease management, hepatoma, hepatitis and HIV co-infection, nonalcoholic steatohepatitis, hepatorenal syndrome, and the care of liver transplant patients.